PharmaCielo (PCLO) Price & Analysis

Q: What was PharmaCielo’s price range in the past 12 months?

PharmaCielo lowest stock price was C$0.03 and its highest was C$0.17 in the past 12 months.

Q: What is PharmaCielo’s market cap?

PharmaCielo’s market cap is C$10.77M.

Q: When is PharmaCielo’s upcoming earnings report date?

PharmaCielo’s upcoming earnings report date is May 04, 2026 which is in 45 days.

Q: How were PharmaCielo’s earnings last quarter?

PharmaCielo released its earnings results on Mar 02, 2026. The company reported C$0.002 earnings per share for the quarter, beating the consensus estimate of N/A by C$0.002.

Q: Is PharmaCielo overvalued?

According to Wall Street analysts PharmaCielo’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does PharmaCielo pay dividends?

PharmaCielo does not currently pay dividends.

Q: What is PharmaCielo’s EPS estimate?

PharmaCielo’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does PharmaCielo have?

PharmaCielo has 187,893,690 shares outstanding.

Q: What happened to PharmaCielo’s price movement after its last earnings report?

PharmaCielo reported an EPS of C$0.002 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 20%.

Q: Which hedge fund is a major shareholder of PharmaCielo?

Currently, no hedge funds are holding shares in TSE:PCLO

Compare

50 Followers

PCLO Stock Chart & Stats

C$0.04

<C$0.01(5.56%)

At close: Jan 08 4:00 PM EST

C$0.04

<C$0.01(5.56%)

Day’s Range― - ―

52-Week RangeC$0.03 - C$0.17

Previous CloseN/A

Volume2.00K

Average Volume (3M)0.00

Market Cap

C$10.77M

Enterprise ValueC$31.52M

Total Cash (Recent Filing)C$289.24K

Total Debt (Recent Filing)C$18.65M

Price to Earnings (P/E)5.2

Beta-2.01

Next Earnings

May 04, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)<0.01

Shares Outstanding187,893,690

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio-0.01

Price to Book (P/B)-0.55

Price to Sales (P/S)3.24

P/FCF Ratio-8.30

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Positive Gross MarginA positive gross margin (~29%) shows the core cultivation and extraction operations can generate unit-level profitability. If management grows sales and contains overhead, this margin provides structural potential to move toward operating leverage and eventual EBITDA improvement.

Improving Cash Burn Vs Prior YearsMaterial reduction in cash outflows versus earlier years indicates the company has curtailed highest-cost activities and is recording operational stabilization. Sustained lower burn increases runway and the chance to reach cash-neutral operations with modest revenue recovery or financing.

Specialized Pharma Cannabis Supply ChainA focused B2B pharmaceutical cannabinoid model and Colombia-based cultivation give structural advantages: specialized regulatory know-how, lower-cost production, and barriers to entry. These traits support durable competitiveness for medical and research customers.

Bears Say

Negative Equity And High LeverageSignificantly negative equity and debt materially impair financial flexibility and elevate insolvency/refinancing risk. Over the medium term this constrains investment, limits access to low-cost capital, and forces strategic trade-offs unless capital structure is repaired.

Persistent Negative Cash FlowOngoing negative OCF and FCF mean the business still consumes cash for daily operations and capex. Without consistent positive cash generation, the company remains dependent on external funding to service debt and invest in growth, raising dilution or default risk.

Falling Revenue & Deep Operating LossesDeclining sales and very negative operating and net margins show the current revenue base cannot support fixed costs or produce sustainable profits. Structural recovery requires consistent revenue growth or meaningful cost restructuring to close the large profitability gap.

PharmaCielo News

PharmaCielo Pays Debenture Interest in Shares Ahead of April AGM

PharmaCielo ( ($TSE:PCLO) ) has shared an update. PharmaCielo Ltd., the Canadian parent of Colombia-based cannabis cultivator and...

3d ago

PharmaCielo Turns EBITDA Positive as It Refocuses on Higher-Margin Exports

PharmaCielo ( ($TSE:PCLO) ) just unveiled an update. PharmaCielo reported results for the quarter and nine months ended...

18d ago

PharmaCielo Sets AGM Date and Moves to Pay Debenture Interest in Shares

An update from PharmaCielo ( ($TSE:PCLO) ) is now available. PharmaCielo Ltd. has scheduled its annual general meeting...

1M ago

PharmaCielo Shares to Resume Trading as Cease Trade Order Lifted and Insider Financing Detailed

PharmaCielo ( ($TSE:PCLO) ) has provided an update. PharmaCielo has had its failure-to-file cease trade order revoked by...

3M ago

PharmaCielo Faces Cease Trade Order Amid Financial Filing Delay

PharmaCielo ( ($TSE:PCLO) ) has issued an update. PharmaCielo Ltd. announced that the Ontario Securities Commission has issued...

8M ago

PharmaCielo Achieves Remarkable Sales Growth and Financial Stability in Q4 2024

PharmaCielo ( ($TSE:PCLO) ) has issued an announcement. PharmaCielo reported a significant financial turnaround in Q4 2024, achieving...

1y ago

PharmaCielo Issues Shares to Settle Debts and Interest

PharmaCielo ( ($TSE:PCLO) ) has issued an update. PharmaCielo announced its plans to issue shares to settle certain...

1y ago

PharmaCielo’s Revenue Soars with Strategic Growth

PharmaCielo (TSE:PCLO) has released an update. PharmaCielo reported an impressive 85% year-over-year sales growth, achieving a total revenue...

1y ago

PharmaCielo Extends Warrant Expiry to Boost Market Position

PharmaCielo (TSE:PCLO) has released an update. PharmaCielo Ltd. has announced its plan to extend the expiry date of...

1y ago

PharmaCielo Shifts Fiscal Year-End and Names New Auditor

PharmaCielo (TSE:PCLO) has released an update. PharmaCielo, a Canadian-based global medical cannabis company, has announced a change in...

1y ago

PCLO FAQ

What was PharmaCielo’s price range in the past 12 months?

PharmaCielo lowest stock price was C$0.03 and its highest was C$0.17 in the past 12 months.

What is PharmaCielo’s market cap?

PharmaCielo’s market cap is C$10.77M.

When is PharmaCielo’s upcoming earnings report date?

PharmaCielo’s upcoming earnings report date is May 04, 2026 which is in 45 days.

How were PharmaCielo’s earnings last quarter?

PharmaCielo released its earnings results on Mar 02, 2026. The company reported C$0.002 earnings per share for the quarter, beating the consensus estimate of N/A by C$0.002.

Is PharmaCielo overvalued?

According to Wall Street analysts PharmaCielo’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does PharmaCielo pay dividends?

PharmaCielo does not currently pay dividends.

What is PharmaCielo’s EPS estimate?

PharmaCielo’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does PharmaCielo have?

PharmaCielo has 187,893,690 shares outstanding.

What happened to PharmaCielo’s price movement after its last earnings report?

PharmaCielo reported an EPS of C$0.002 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 20%.

Which hedge fund is a major shareholder of PharmaCielo?

Currently, no hedge funds are holding shares in TSE:PCLO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

PharmaCielo

PharmaCielo Ltd., together with its subsidiary, cultivates, processes, produces, and supplies medicinal-grade cannabis extracts, tetrahydrocannabinol, and related products. The company also offers telemedicine software. It serves health and wellness product manufacturers, pharmacies, medical clinics, and cosmetic companies in Canada and Colombia. The company has a strategic alliance with AssuredTrans Inc. PharmaCielo Ltd. is headquartered in Toronto, Canada.